A New Standard of Automated Cell counter
ADAM™-MC, the automated fluorescence cell counter, performs viability and cell counting measurements using the PI(Propidium Iodide) staining method of dead-cell staining combined with advanced image analysis.
- Less than 1 min to get results
- Automated image analysis
- Accurate result
- Sensitive CCD detection and precise automatic stage
- Auto focusing
ADVANTAGE #1
New Standard of Automated Cell Counting
The ADAM™ series automatic cell counter measures total cell numbers and cell viability through cutting-edge detection technologies.
Instead of trypan blue staining which can lead to inaccurate data, ADAM™ utilizes sensitive fluorescence dye staining, LED optics and CCD detection technologies.
ADVANTAGE #2
Principle of Viability Measurement (PI-Staining Method)
After the samples are stained with fluorescent dye, propidium iodide, which intercalates DNA to stain the nucleus of target cells, ADAM™-MC takes fluorescent images automatically. The obtained images are processed by image analysis software integrated inside the system
ADVANTAGE #3
Disposable Microchips
The ADAM™ series automated cell counter utilizes a precision disposable microchip to eliminate the problem of a permanent counting chamber.
Each microchip is designed for single use. Pumping, cleansing, and wasting slides are not necessary for the ADAM™ cell counter.
Each microchip is produced at our state-of-the-art manufacturing facility and validated for accuracy.
ADVANTAGE #3
Accuracy & Reproducibility
ADVANTAGE #4
Comparison with Flow Cytometry
Comparison of cell viability between ADAM™ and flow cytometry.
SK-OV, HeLa and NCI-H23 cells were treated with 100 and 300 μM of H2O2 for 3 hours, then analyzed by ADAM™ and flow cytometry.
Values are given as mean ± SD of three experiments.
Reference paper of using ADAM™-MC
1. 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation, Cellular & molecular immunology 14.9 (2017): 748-757.
2. The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential, Cancer letters 382.2 (2016): 188-194
3. Phase I Clinical Trial of 4-1BB-based Adoptive T-cell therapy for Epstein-Barr Virus (EBV)-positive tumors, Journal of Immunotherapy (Hagerstown, Md.: 1997) 39.3 (2016): 140.
FOR RESEARCH USE ONLY.
This product is not approved for diagnostic or therapeutic use.
Visit NanoEntek blog now!
Want to learn more about cell counting and cell therapy?
Visit to find out more!
blog-nanoentek.com
